New research examines the role of factor Xa in the pathology of antiphospholipid syndrome (APS) and systemic lupus erythematosus-associated APS. Researchers found that FXa stimulation was mediated by protease-activated receptors and enhanced by IgG from FXa reactive antibody positive patients, which may make IgG FXa reactivity a novel biomarker for future research…
The ACR, EULAR Partner to Refine Classification System, Develop New SLE Criteria
MADRID—Systemic lupus erythematosus (SLE) experts in North America and Europe are working together to refine the classification system for the disease, with the goal of producing a new set of criteria that is simpler to use and more scientifically rigorous than any classification approach previously published, speakers involved with the process said at the 2017…
Bipolar Disorder, Nailfold Capillaroscopy Score, Urban Location Among Risk Factors for Developing Lupus
MADRID—Researchers have found that systemic lupus erythematosus (SLE) is independently linked with bipolar disorder and say the findings point to a need for greater awareness of psychiatric problems in patients with SLE. In work led by investigators at Tel Aviv University in Israel and presented at the 2017 Annual European Congress on Rheumatology (EULAR), researchers…
Accelerating Medicines Partnership Shares Its Progress on RA/Lupus Network
CHICAGO—“Why do so many drugs fail in clinical trials?” asked Michael Brenner, MD, chief of rheumatology, immunology and allergy at Brigham and Women’s Hospital in Boston. This question, previously posed by Francis Collins, MD, PhD, director of the National Institutes of Health, prompted a discussion among scientists and stakeholders in the pharmaceutical industry. The conversation…
Rituximab May Help Pediatric Patients with SLE
Although rituximab is not indicated for adults with SLE, a recent review suggests that it may be safe and effective for treating pediatric SLE. The review found that rituximab improved renal function and reduced proteinuria in pediatric patients. It may also prevent relapse and improve disease activity…
ARHP Clinical Focus Course Targets Management of Adults with SLE
This year the ARHP Clinical Focus Course brings together experts in the field to provide an interprofessional approach to the management of systematic lupus erythematosus (SLE) to improve patient outcomes. The daylong course, titled Systemic Lupus Erythematosus: Taming the Wolf—Salient Lessons from Practice and Research, which is offered on Nov. 4, will provide a case-based…
Dr. Peter Schur Discusses Lupus Treatment, Management Advances in Past 50 Years
Although systemic lupus erythematosus still does not have a definite cause or cure, rheumatologists and researchers over the past 50 years have witnessed and contributed to a great deal of progress that helps patients, says Peter H. Schur, MD, director emeritus of the Lupus Center, Brigham and Women’s Hospital, and professor, Harvard Medical School, Boston. Dr. Schur’s…
Infection Rates for Patients with SLE on Immunosuppressive Drugs
A comparison study of the serious infection burden among patients with lupus found no major differences in patients treated with three separate immunosuppressive drug regimens. Given that serious infections are among the leading causes of hospitalizations and death in patients with systemic lupus erythematosus (SLE), researchers investigated whether the incident rates differed in patients who…
Newly Diagnosed SLE Patients Have a Greater Risk of Cardiovascular Disease
New research has examined the risk of cardiovascular disease (CVD), as well as myocardial infarction and ischemic stroke, for patients with systemic lupus erythematosus (SLE) in a large-scale population-based study. Researchers found that patients with SLE have a greater than two-fold increased risk of developing CVD. This risk is greatest during the first year after diagnosis and remains elevated for at least five years…
BAFF: A Fulcrum Between Resistance to Infection & Autoimmunity
New research has linked a TNFSF13B variant and B cell activating factor (BAFF), a common therapeutic target, with multiple sclerosis and systemic lupus erythematosus. The variant is a disease-risk allele associated with increased levels of soluble BAFF…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 10
- Next Page »